Alumis Inc.
ALMSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAlumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The $881.5M market capitalization puts ALMS squarely in small-cap range for its industry. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Market Cap
$881.5M
Beta
-0.36
P/E (TTM)
—
P/E (Fwd)
-2.37
EPS (TTM)
$-3.92
EPS (Fwd)
$-2.87
ROE
-93.7%
ROA
-45.3%
Cash
$502.3M
Total Debt
$36.4M
Free CF
-$208.6M
52W Change
51.7%
Annual Financials
Cash vs Debt
Where ALMS stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, ALMS finished 71.40% below its 150-day moving average ($21.19) and 72.39% below its 200-day moving average ($21.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALMS overbought or oversold?
At the October 15, 2026 close, ALMS's RSI(14) was 27.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $502.3M in cash and $36.4M in debt, ALMS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$208.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -93.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Alumis Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Alumis Inc.'s trajectory.